Anti-IL-17 use is well established and approved in psoriatic arthritis, and has demonstrated a therapeutic action not only in several tumor forms [48], but also in the therapy of lung infections due to the H1N1 virus [47], ARDS [49], and pulmonary fibrosis [50]. Here, IL17A is linked to acute respiratory distress syndrome.